Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
3.510
-0.080 (-2.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
November 18, 2022
Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell...
Via
Benzinga
Intuit To $490? Here Are 5 Other Price Target Changes For Friday
November 18, 2022
Barclays cut Intuit Inc. (NASDAQ: INTU) price target from $502 to $490. . Barclays analyst Raimo Lenschow maintained an Overweight rating on the stock. Intuit shares fell 3% to close at $381.88 on...
Via
Benzinga
Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50%
November 18, 2022
Telsey Advisory Group boosted the price target on The Gap, Inc. (NYSE: GPS) from $10 to $15. Gap shares rose 5.6% to close at $12.71 on Thursday.
Via
Benzinga
Why Editas Medicine's Shares Are Falling Thursday
November 17, 2022
The company shelved a clinical trial for one of its lead therapies.
Via
The Motley Fool
Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings
November 17, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday.
Via
Benzinga
Editas Medicine: Q3 Earnings Insights
November 02, 2022
Editas Medicine (NASDAQ:EDIT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Editas Medicine's Return On Capital Employed Insights
August 10, 2022
Via
Benzinga
Editas Medicine: Q2 Earnings Insights
August 03, 2022
Editas Medicine (NASDAQ:EDIT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
November 18, 2022
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.
Via
Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
November 17, 2022
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67...
Via
Benzinga
Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder
November 17, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 17, 2022
Via
Benzinga
S&P 500 Down 1%; Crude Oil Drops Sharply
November 17, 2022
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday.
Via
Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
November 17, 2022
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 17, 2022
Via
Benzinga
BMO Initiates Coverage On This Gene Editing Spearhead
June 17, 2022
Via
Benzinga
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
November 17, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About Editas Medicine
November 03, 2022
Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
November 02, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
October 26, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
October 13, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
September 29, 2022
Upgrades
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
3 Biotech Stocks Gaining Momentum
September 12, 2022
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.
Via
MarketBeat
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
July 27, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
July 26, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.
Via
InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
June 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.